KRAS and lung neoplasm: However, the preliminary results of the studies in an animal model showed that the use of CB-839 as monotherapy in lung tumors with the K-Ras mutation did not give satisfactory results; for this reason, it is suggested to include selective inhibitors of glycolysis as well [171].